| SITE MAP |
Having trouble finding something?
Use our site map. |
|
|
|
|
From a clinical to commercial level, nm|OK is used for such tasks as:
Rapid assessment of the development status of thousands of products
By using nm|OK, executives can obtain an immediate assessment of the development status of:
- one specific drug using any name, old or new, assigned to that drug
- a group of drugs addressing a certain cancer or clinical indication, such as lung cancer, or non-small cell lung cancer (nsclc), or extended disease small-cell ling cancer, etc.
- a group of drugs by development status, i.e., drugs in phase I, II, or III clinical trials and those in preclinical or research stage
- a class of drugs acting by a well defined mechanism, such as regulating agents (inhibitors of oncogenes, receptor ligands, etc.), cytotoxics (microtubule stabilizers, DNA intercalators, immunotoxins, etc.), immunotherapeutics (therapeutic vaccines, immunomodulators, etc.)
- various technologies such as synthetic nucleic acid sequences, monoclonal antibodies, gene transfer therapy, oncolytic viruses, etc.
- novel drug delivery systems such as sustained release, depots, pulmonary delivery, vectors, etc
- thousands of protocols and interim/final results from clinical trials, by cancer and clinical indication, including dates of initiation/completion, trial locations and principle investigators/study chairs
Note: Any of the above criteria may be combined to narrow or expand a search
Market research, due diligence and competitive assessment
By using nm|OK, executives can assess product/company acquisition options and licensing opportunities, allowing them to design competitive strategies. nm|OK is unique as it links products/technologies developed in-house with those being developed by others under various types of strategic alliances, to allow users to view comprehensive company pipelines. Also, global revenues are presented for major marketed oncology products to establish worldwide market opportunities.
Evaluation of proposals/reports submitted by third parties
By using nm|OK executives would speed up the preparation/review of proposals to perform custom projects and also ensure that the results of such assignments are representative of the status of the oncology sector in evaluation.
Evaluation of R&D investments
By accessing nm|OK, R&D executives are able to tap into a vast body of clinical and technological advances in this field and make informed decisions as to in-house research and collaborations with others.
Education
Companies with expanding product lines in oncology can use nm|OK as an educational tool for executives during reassignment or upon the introduction of new products.
|
|
